Companies like Genentech are hoping that personalized cancer vaccines take off, MIT's Technology Review reports.

It notes that the leadership there was initially skeptical that such a treatment could work, but in the years since, advances in genome sequencing as well as figuring out why the human immune system would target some cancer antigens but not other proteins, have helped them and others come around.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.